Paul D Rubin

USPTO Granted Patents = 36 (Patent Applications = 3)

CIPO Patents = 3 (Patent Applications = 16)

Average Co-Inventor Count = 1.9

ph-index = 10

Forward Citations = 327(Granted Patents)

Company Filing History:

Sunovion Pharmaceuticals Inc.

patents

4. 1 out of 832,680

Other

patents

Years Active: 1999-2013

Loading Chart...

36 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 8404715 - Methods and compositions using racemic, (R)-, and (S)-fexofenadine in combination with leukotriene inhibitors (2013-03-26),

2. 7064138 - Methods for treating irritable bowel syndrome using optically pure (-) norcisapride (2006-06-20),

3. 7030142 - Methods for the treatment of neuroleptic and related disorders using ziprasidone metabolites (2006-04-18),

4. 6946464 - Methods of treating and preventing a convulsive state (2005-09-20),

5. 6835740 - Methods for treating sleep apnea and sleep induced apnea using optically pure (+) norcisapride (2004-12-28),

6. 6790849 - Methods and compositions using optically pure (-) cetirizine in combination with leukotriene inhibitors or decongestants (2004-09-14),

7. 6649183 - Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron (2003-11-18),

8. 6620851 - Methods for the treatment of neuropathic pain and other disorders using R(−)-ketoprofen (2003-09-16),

9. 6586437 - (S)-hydroxynefazodone antipsychotic therapy (2003-07-01),

10. 6559165 - Methods for treating bulimia using optically pure (−) norcisapride (2003-05-06),

11. 6552045 - Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists (2003-04-22),

12. 6548518 - Methods of treating gastro-esophogeal reflux disease using (-) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists (2003-04-15),

13. 6548082 - Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron (2003-04-15),

14. 6509353 - Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors (2003-01-21),

15. 6506753 - Methods of making and using N-desmethylzopiclone (2003-01-14),

Title: The Innovative Contributions of Paul D Rubin: A Focus on Patented Pharmaceutical Advancements

Introduction: Paul D Rubin, a prominent inventor hailing from Sudbury, Massachusetts, has made significant strides in the field of pharmaceuticals. With an impressive portfolio of 36 patents, Rubin has focused his efforts on developing innovative methods and compositions that address various health conditions, particularly those related to allergies and gastrointestinal disorders.

Latest Patents: Rubin's most recent patents demonstrate his expertise in combining pharmaceutical agents for enhanced treatments. One notable patent outlines methods and compositions using racemic, (R)-, and (S)-fexofenadine paired with leukotriene inhibitors. This innovation aims to improve the treatment of inflammation and allergic disorders, including asthma. Additionally, he has developed methods that utilize a terfenadine metabolite and leukotriene inhibitors, enhancing the therapeutic options available for managing these conditions. Another of his significant contributions is the method for treating irritable bowel syndrome with optically pure (-) norcisapride, a treatment strategy designed to deliver effective outcomes while minimizing unwanted stereoisomers.

Career Highlights: Throughout his career, Paul D Rubin has been associated with notable organizations such as Sepracor, Inc. and Swpracor, Inc., where he has worked on pioneering developments in the pharmaceutical industry. His persistent dedication to research and development has led to advancements that have broad implications for patient care.

Collaborations: Rubin’s endeavors in the field have also been marked by collaborations with esteemed colleagues, including Timothy J Barberich and Thomas P Jerussi. Such partnerships have further enriched his work, fostering a collaborative environment focused on innovation and excellence in pharmaceutical sciences.

Conclusion: The contributions of Paul D Rubin serve as a testament to the impact of innovation within the field of pharmaceuticals. His extensive portfolio of patents not only reflects his dedication to advancing medical science but also underscores the importance of collaboration in achieving meaningful healthcare solutions. As the industry continues to evolve, Rubin's work will undoubtedly inspire future generations of inventors and scientists aiming to improve patient outcomes through innovative strategies.

This text is generated by artificial intelligence and may not be accurate.